What is Developmental Therapeutics?

Developmental therapeutics is clinical research aimed at finding new and innovative anti-cancer therapies. It includes the exploration of new drugs, new combinations of drugs, new technologies, and new cell and immune therapies for cancer treatment. Once identified, these new therapies are tested in patients for safety, appropriate dosing and efficacy within the confines of a clinical trial. The ultimate goal is to identify novel therapies that are safe and effective in treating children with cancer, while also preserving their quality of life. 

What is a clinical trial?

According to the World Health Organization (WHO), a clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

In other words, clinical trials are research studies performed on patients that are aimed at evaluating how a specific medical, surgical or behavioral intervention impacts them and their disease. Clinical trials are the primary way researchers find out if a new treatment, such as a new drug to fight leukemia, is safe and effective in patients. There are four phases of clinical trials — each with unique and specific goals. 

  • Phase I trial
    • This trial typically tests a new treatment on a small group of patients in order to understand the best dose and side effects of the drug or drug combination. Although the hope is that this new treatment is effective, this is not the goal of the trial. 
  • Phase II trial
    • While the emphasis in phase I trials is on is on safety, the emphasis in a phase II trial is to test how effective a new treatment is in treating a disease on a specific group of patients. Phase II trials usually enroll more patients than a phase I trial. Phase II trials also continue to study safety, including short and long-term side effects.
  • Phase III trial
    • This trial typically tests a new drug or drug combination and compares it to the best-known therapy (the standard of care) to evaluate if it is more or less effective.
  • Phase IV trial
    • This type of trial takes place after the U.S. Food and Drug Administration (FDA) approves the use of a specific drug, drug combination or device. A device or drug's effectiveness and safety are monitored in large, diverse populations. Pediatric drugs rarely undergo phase IV testing.

Who do we treat?

We treat children and young adults with cancer that has not responded well or progressed after what is considered the best therapy. We may also treat children with a specific diagnosis that has a poor outcome despite the best-known therapies. The Developmental Therapeutics team treats children and young adults enrolled on Phase I and Phase II clinical trials.

Why is it important?

Phase I and II trials evaluate new and innovative treatments. They provide additional options for children who in the past had limited treatment choices outside of standard therapy. These trials allow researchers to better understand new treatments, including their side effects, the most appropriate doses to use in children and young adults and learn how a specific tumor responds to these new therapies. This process helps inform more effective and future treatments for children and young adults with cancer.

Our Unique Approach

At the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta, our goal is to shift ideas from the lab to the bedside of patients when it is suitable for clinical trials.

Our Development Therapeutics (Dev-T) Program focuses on the creation of new treatments for children and young adults with cancer and blood disorders. Our hope is that new drugs, new combinations of drugs or technologies lead to new and safe effective therapies to help fight pediatric cancer while minimizing side effects whenever possible.

Program highlights

  • We are proud to provide numerous unique local trials developed and led by our very own clinical research team members.  These include trials treating children with a variety of recurrent and high risk cancers.  Information on many of these trials can be found here.
  • We are members of the Children’s Oncology Group (COG) Pediatric Early Phase-Clinical Trial Network (PEP-CTN)—one of only 21 centers nationally. This prestigious membership allows us to offer novel and innovative therapies to children and young adults with a wide range of different cancer diagnoses. Visit the PEP-CTN and COG's website for more information.
  • We are one of 12 national members of the Pediatric Brain Tumor Consortium (PBTC), a consortium dedicated to providing new and innovative therapies to children with recurrent or progressive and high-risk brain tumors. Visit PBTC's website for more information.
  • We are members of the New Approaches to Neuroblastoma Therapy (NANT), a consortium dedicated to developing new therapies specifically for children with neuroblastoma, therefore improving their outcome and minimizing side effects. Visit NANT's website for more information.>
  • We are members of Therapeutic Advances in Childhood Leukemia (TACL), a consortium dedicated to developing innovative therapies for incurable leukemia and lymphoma. Visit TACL's website for more information.
  • The Developmental Therapeutics team partners with our Bone Marrow Transplant team to provide patients with new and innovative cellular therapies. 
  • The Aflac Cancer Center has dedicated providers who specialize in Palliative Care to help support our Developmental Therapeutics patients.

Is my child eligible for a clinical trial at the Aflac Cancer and Blood Disorders Center?

While we have several open trials that are currently accruing new patients, it is often difficult to know if your child is eligible for a specific trial until we know more about your child’s cancer, previous treatments and medical history.

If you have questions regarding your child’s eligibility for a specific trial, please contact us using the contact information below.

Kate Glasscox, BSN, RN CPN
Developmental Therapy Clinical Nurse Coordinator
Aflac Cancer Center
Office:404-785-0002
Email: Katherine Glasscox

Learn more about research at the Aflac Cancer Center

Find a clinical trial

Meet the Team

Our developmental therapeutics team

Advanced Practice Providers

Patient Care Navigator

  • Kate Glasscox, BSN, RN, CPN

Research Coordinators

  • Amy Autry-Bush, BS, CCRP, Lead Research Coordinator
  • Melissa Schink, MSN, RN
  • Olivia Floyd, BSN, RN
  • Christie Frick, BSN, RN, CPN
  • Amber Kaminski, MSN, RN
  • Bailey Sturdivant, BS, CRC

Solid Tumor and MIBG Clinical Nurse Coordinator

  • Sarah Carlin, BSN, RN, CPHON